Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CET

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
12/06 AMGEN : How These Biotech Stocks are Faring? -- Celgene, Sarepta Therapeutics, M..
12/03 AMGEN : Cal Lutheran's newest MBA aimed at working professionals
12/02 AMGEN : Announces Launch Of Blood Counts™ And Collaboration With StoryCorp..
12/02 CYTOKINETICS : Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omeca..
12/02 AMGEN : And Allergan Submit Biosimilar Marketing Authorization Application To Eu..
12/01 AMGEN : To Present At The Citi 2016 Global Healthcare Conference
12/01 ARROWHEAD PHARMACEUTICALS : Announces Closing of License and Collaboration Agree..
11/30 AMGEN : Cholesterol drug shows promise to help reverse heart disease
11/30 AMGEN : Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Mult..
11/24 AMGEN : Assigned Patent
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/05 Precision AML Trial Adds Pharma Candidates To The Mix
12/05 Investor Movement Index (IMX) For November 2016
12/05 NOVEMBER PORTFOLIO ROUNDUP : 2 Buys, 1 New Position
12/02 Amgen submits European marketing application for Avastin biosimilar
12/01 Cytokinetics earns $26.7M milestone from Amgen on start of large-scale CV out..
Financials ($)
Sales 2016 22 793 M
EBIT 2016 11 081 M
Net income 2016 7 646 M
Debt 2016 2 579 M
Yield 2016 2,69%
P/E ratio 2016 14,31
P/E ratio 2017 13,59
EV / Sales 2016 4,85x
EV / Sales 2017 4,57x
Capitalization 107 951 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 183 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.-10.50%107 951
GILEAD SCIENCES, INC.-28.38%95 476
ACTELION LTD45.20%21 783
More Results